Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′- C -Methylcytidine, the Active Component of Valopicitabine-Reference-Cited by-同舟云学术

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′- C -Methylcytidine, the Active Component of Valopicitabine

Published:2006-10 Issue:10 Volume:50 Page:3444-3446
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Coelmont Lotte¹,Paeshuyse Jan¹,Windisch Marc P.²,De Clercq Erik¹,Bartenschlager Ralf²,Neyts Johan¹

Affiliation:

1. Rega Institute for Medical Research, KULeuven, 3000 Leuven, Belgium

2. Department of Molecular Virology, University of Heidelberg, 69120 Heidelberg, Germany

Abstract

ABSTRACT Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2′- C -methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2′- C -methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00372-06

Reference13 articles.

1. Afdhal, N., E. Godofsky, J. Dienstag, V. Rustgi, L. Schick, D. McEniry, X. J. Zhou, G. Chao, C. Fang, B. Fielman, M. Myers, and N. Brown. 2004. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology40:726A.

2. Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

3. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem.278:11979-11984.

4. De Francesco, R., and G. Migliaccio. 2005. Challenges and successes in developing new therapies for hepatitis C. Nature436:953-960.

5. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and Biological Activities of Some 1,2,4-Triazole Derivatives: A Review;Al Mustansiriyah Journal of Pharmaceutical Sciences;2022-10-24

2. Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics;International Journal of Nanomedicine;2021-07

3. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates;Antiviral Research;2020-05

4. Antiviral candidates against the hepatitis E virus (HEV) and their combinations inhibit HEV growth in in vitro;Antiviral Research;2019-10

5. Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes ribavirin;Archives of Virology;2017-06-16